Tirzepatide
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
Eli Lilly · Phase 2 · Completed · Enrollment 354
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Dosing scheme a: NNC0519-0130 | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme a: Placebo | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme b: NNC0519-0130 | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme b: Placebo | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme c: NNC0519-0130 | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme c: Placebo | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme d: NNC0519-0130 | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme d: Placebo | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme e: NNC0519-0130 | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme e: Placebo | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme f: NNC0519-0130 | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme f: Placebo | Obesity or overweight | n/r | 42 | n/r | n/r |
| Dosing scheme g: Tirzepatide | Obesity or overweight | n/r | 42 | n/r | n/r |